PubRank

P Y Scarabin

Author PubWeight™ 25.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Use of monitoring software to improve the measurement of carotid wall thickness by B-mode imaging. J Hypertens Suppl 1992 1.22
2 Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996 1.16
3 Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990 1.03
4 Risk factors for early carotid atherosclerosis in middle-aged French women. Arterioscler Thromb 1991 1.02
5 Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet 1999 0.96
6 Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome. J Pediatr 1987 0.95
7 The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995 0.93
8 Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women. Clin Pharmacol Ther 2010 0.93
9 Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost 2009 0.93
10 Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997 0.91
11 Diagnostic accuracy of compression ultrasonography for the detection of asymptomatic deep venous thrombosis in medical patients--the TADEUS project. Thromb Haemost 2001 0.90
12 Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 1989 0.89
13 Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006 0.86
14 Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999 0.85
15 Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 1980 0.84
16 Further evidence that activated factor VII is related to plasma lipids. Br J Haematol 1985 0.84
17 Early carotid atherosclerosis in healthy middle-aged women. A follow-up study. Stroke 1993 0.83
18 Longitudinal associations between plasma viscosity and cardiovascular risk factors in a middle-aged French population. Atherosclerosis 1993 0.82
19 Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. Arterioscler Thromb Vasc Biol 2001 0.82
20 Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 1988 0.81
21 Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996 0.81
22 The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost 2001 0.79
23 Increased risk of atherosclerosis in women after the menopause. BMJ 1989 0.77
24 [Deep venous thrombosis: epidemiology, acquired risk factors]. Ann Cardiol Angeiol (Paris) 2002 0.76
25 Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction Study. Atherosclerosis 2001 0.76
26 Safety of combined oral contraceptive pills. Lancet 1996 0.75
27 Re: "Hormone replacement therapy and risk of hospitalization for venous thromboembolism: a population-based study in southern Europe". Am J Epidemiol 1999 0.75
28 Seasonal variations of plasma fibrinogen in elderly people. Lancet 1994 0.75
29 Risk of venous thrombosis with hormone replacement therapy. Lancet 1996 0.75
30 [Hormone replacement therapy of menopause and mortality]. Rev Epidemiol Sante Publique 1997 0.75
31 A multicenter study on amidolytic factor X evaluation in oral anticoagulant therapy. Thromb Haemost 1985 0.75
32 HRT and ACE activity in postmenopausal women. Lancet 1996 0.75
33 Reliability of a single beta-thromboglobulin measurement in a diabetic population: importance of PGE1 in anticoagulant mixture. Damad Study Group. Thromb Haemost 1987 0.75
34 Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME study. J Hum Hypertens 2000 0.75
35 Platelet aggregation related to age in diabetes mellitus. Haemostasis 1980 0.75
36 Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy? The Damad Study Group. Thromb Haemost 1990 0.75
37 Relationship between antithrombin III, antiplasmin and plasma lipids in a healthy population. Thromb Haemost 1983 0.75
38 [Essential arterial hypertension. Study of platelet aggregation]. Nouv Presse Med 1980 0.75
39 [Measurement of platelet volume: methodologic approach and application in diabetes]. Nouv Rev Fr Hematol 1982 0.75
40 Effect of age on ADP-induced platelet aggregation in diabetic and non-diabetic subjects. Thromb Res 1982 0.75
41 [An application of Mantel's test to the analysis of some biological assays (author's transl)]. Rev Epidemiol Sante Publique 1980 0.75
42 Factor VII activation and oral contraceptives. Thromb Res 1993 0.75
43 Plasma 17beta estradiol is inversely correlated with circulating vascular cell adhesion molecule. Thromb Haemost 2000 0.75
44 [Hormone replacement therapy in menopause and the risk of cerebrovascular accident]. Ann Endocrinol (Paris) 1999 0.75
45 Is factor VII activation in pregnant women relevant to fetal growth retardation? Thromb Res 1987 0.75